Gencurix Receives Australian Government Approval for Droplex POLE Mutation Test

Gencurix Receives Australian Government Approval for Droplex POLE Mutation Test

SEOUL, South Korea, Oct. 12, 2023 /PRNewswire/ -- Gencurix, a cancer molecular diagnostics company, has obtained approval from the Australian Government (The Department of Health and Aged Care, Therapeutic Goods Administration) for its Droplex POLE...

menu
menu